Owlstone Medical advancing against cancer

Published on: 9 May 2017, under Breath Biopsy

Owlstone Medical has been featured in Pharmaphorum’s “Deep Dive Oncology” magazine. The article lists 5 companies leading the next generation of innovation in the cancer space, and describes our Breath Biopsy® platform, including our lung cancer collaboration with the NHS through the LuCID clinical trial. 


Five tech companies advancing against cancer

Marco Ricci – May 2017

Excerpt from the article:

“The advantage to VOCs is that they can be picked up earlier than signatures searched for in liquid biopsies, meaning cancer can be diagnosed earlier and treated more effectively.”

Media contact

For more information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730 919

Owlstone  world-leading team provides a range of premium services for non-invasive diagnostics

Our expert team can support every step of your breath biomarker research from study design to data analysis

View our services